Your institution may have access to this item. Find your institution then sign in to continue.
Title
Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.
Authors
Farlow, Martin R; Grossberg, George T; Meng, Xiangyi; Olin, Jason; Somogyi, Monique
Abstract
The cholinesterase inhibitor rivastigmine is approved for the symptomatic treatment of mild to moderate Alzheimer's disease (AD). This exploratory, hypothesis-forming analysis assessed response to rivastigmine according to severity of dementia at baseline.
Publication
International journal of geriatric psychiatry, 2011, Vol 26, Issue 12, p1236